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Abstract
Background: Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystemic involvements
including a progressive loss of maximal muscle strength and muscle wasting. Poor lower-limb strength is an important
factor explaining disrupted social participation of affected individuals. This review aims to map what is known about the
effects of exercise and training programs undertaken to counteract skeletal muscle impairments in DM1 patients.
Methods: Medline, CINAHL and EMBASE databases were searched. Regarding study eligibility, title and abstract of 704
studies followed by 45 full articles were reviewed according to the following eligibility criteria. Inclusion: (1) humans with
DM1 and (2) experimental protocol relying on exercise or training. Exclusion: (1) studies that do not evaluate skeletal
muscle responses or adaptations, (2) reviews covering articles already included and (3) pharmacological intervention at
the same time of exercise or training program.
Results: Twenty-one papers were selected for in-depth analysis. Different exercise or training protocols were
found including: acute exercise, neuromuscular electric stimulation, strength training, aerobic training, balance
training and multiple rehabilitation interventions. Seven studies reported clinical measurements only, five physiological
parameters only and nine both types.
Conclusion: This scoping review offers a complete summary of the current scientific literature on the effect of exercise
and training in DM1 and a framework for future studies based on the concomitant evaluation of the several outcomes
in present literature. Although there were a good number of studies focusing on clinical measurements, heterogeneity
between studies does not allow to identify what are the adequate training parameters to obtain exercise
or training-induced positive impacts on muscle function. Scientific literature is even more scarce regarding
physiological parameters, where much more research is needed to understand the underlying mechanisms of
exercise response in DM1.
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Background
Myotonic dystrophy type 1 (DM1) is an autosomal dom-
inant degenerative neuromuscular disease [1–3] caused
by a nucleotide triplet (CTG) repeat expansion within
the 3′ untranslated region of the Dystrophy Myotonic
Protein Kinase (DMPK) gene [4]. The discovery of the
defective gene was made in 1992, which subsequently
allowed a more accurate diagnosis [4]. CTG repeat
length is usually moderately correlated with earlier dis-
ease onset and more severe symptoms [5]. There are
four to five recognized phenotypes: congenital, infantile/
childhood, juvenile, classical/adult and late-onset [5].
DM1 is a multisystemic disease that affects skeletal
muscles and cardiac, digestive, nervous and endocrine
systems, to name a few. Typical signs and symptoms in-
clude myotonia, heart arrhythmias, cataracts, daytime
sleepiness, cognitive impairments, apathy and muscle
wasting and weakness. The latter is a major concern for
affected people, which can lose up to 30.3 to 54.5% of
maximum strength on a 9 year period with a progression
pattern from distal to proximal muscles [6]. A recent
study has shown that even DM1 patients classified in
the first two grades of Muscle Impairment Rating Scale
(MIRS) [7], which are considered to have no limb mus-
cles weakness, show a 11.3 to 24.1% of maximal strength
loss in lower limb muscle groups compared to predicted
values [8]. Muscle weakness is a major culprit for restric-
tions in activities of daily living and social roles [9].
Although the physiological mechanisms are not yet fully
understood, one of the main mechanisms linking the
CTG repetitions to the symptoms in DM1 is the accumu-
lation of toxic CUG RNA causing splicing difficulties by
sequestrating RNA-binding proteins such as muscle
blindlike-1 (MBNL-1) [10]. Originating from this, many
physiological impairments have been identified in skeletal
muscle affected by DM1 that could contribute to muscle
weakness. At a histological level, preferential atrophy of
type I myofibers, higher proportion of centrally nucleated
fibers, fibrosis and fat infiltration have been reported [11].
Moreover, level of expression of glycogen synthase kinase
3 beta (GSK3β), a negative regulator of muscle protein
synthesis, is increased [12]. Thereafter, myogenic capacity
is also perturbed as demonstrated by decreased prolifera-
tive capacity and premature senescence of satellite cells
(muscle stem cells) and delayed fusion and differentiation
of myoblasts (activated satellite cells) [13–17]. An increase
in protein degradation and a decrease in protein synthesis
[1, 18–20], as well as perturbed local and systemic
inflammatory statuses [21, 22], have also been reported.
Finally, a mouse model study has also shown that calcine-
urin is overexpressed in DM1, arguing that it may be a
compensatory mechanism due to its essential role in
muscle hypertrophy [23]. This study also showed that
symptoms worsened in affected mice where calcineurin
was downregulated [23]. These findings only present an
incomplete view of muscle physiology in DM1, and know-
ledge about immediate responses and long-term adapta-
tions to exercise or training are essential for a complete
understanding.
One of the main strategies to counter maximal muscle
strength loss and muscle wasting is through exercise and
training. However, to be effective, exercise and training
need to be specifically adapted to a population and based
on an appropriate dosage. Furthermore, a rationale
based on physiological knowledge is a key point to
properly adapt training to populations with a specific
pathology. In DM1 population, while the underlying
mechanism remain unclear given the small number of
studies along with the small number subjects included
in these, training-induced positive skeletal muscle
adaptation seems possible in DM1. Indeed, it has been
shown that training can induce increase in myofiber
cross-sectional area without causing any histopatho-
logical abnormalities [3, 24]. These results suggest that,
in addition to the positive clinical impact of exercise in
DM1 such as muscle strength gains, exercise should
physiologically work in this disease. A systematic review
has shown strength training to be safe [25], but has not
concluded about its effect on skeletal muscle impair-
ments given the insufficient body of literature. However,
the Cochrane review did not look in detail at the type of
training nor at the type of intervention outcomes (fun-
damental or clinical measures) that were studied. This
last aspect is particularly important because skeletal
muscle responses and adaptations to exercise and
training do not limit themselves to maximal strength or
endurance gains; many changes can occur at a physio-
logical, functional or participation levels. A better under-
standing of the physiological responses and adaptations
can also help uncover new intervention possibilities,
such as a pharmaceutical agent combined with exercise
or training to limit muscle impairments. Therefore, the
main purpose of this scoping review is to map the exist-
ing literature relative to the effects of exercise and train-
ing undertaken to limit skeletal muscle impairments in
DM1 and thereby identify gaps in the literature and
informing where more research is needed. Cochrane sys-
tematic review methodology, which is more restrictive in
their study selection, cannot be used to undertake this
type of mapping of the literature.
Methods
In this review, the framework Methodology for JBI Scop-
ing Reviews was used to develop the methods [26]. This
framework is the best to use in this review because it
has been designed to be broad enough to include any
kind of existing scientific literature, thus allowing the
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most complete mapping on the desired subject and
allowing to better achieve the objective of this study.
Research question
The scoping review aimed to answer the following ques-
tion: “What is known about the effects of exercise and
training that aim to reduce skeletal muscle impairments
of patients with myotonic dystrophy type 1?” The question
was built using the PCC (population, context and concept)
model [26] where DM1 was the population, exercise or
training were the context and muscle responses or adapta-
tions (clinical or physiological) were the concept.
Identifying relevant studies
A systematic literature search was undertaken on Febru-
ary 16th, 2017 with no date limitations to identify all
relevant studies. The search was organised into three
main concepts and sub-concepts: concept 1-myotonic
dystrophy, concept 2-clinical interventions (2a: exercise
training, 2b: rehabilitation), and concept 3-muscle (see
Supplemental digital content 1).
These three concepts allow the identification of appropri-
ate keywords thesaurus and synonyms according to each
database. Four databases were searched: Additional file 1:
Medline (EBSCO), Pubmed, CINAHL (EBSCO) and
EMBASE. Duplicates and articles that were not in French
or in English were removed (119 articles were removed due
to language). The search strategy was reviewed by a know-
ledge broker. A total of 704 articles were obtained (690
English and 14 French).
Study selection
Two independent reviewers (M-PR and MM) screened
the article titles and abstracts according to the following
inclusion and exclusion criteria. Inclusion: (1) humans
with DM1 and (2) experimental protocol relying on ex-
ercise or training. Exclusion: (1) studies that do not
evaluate skeletal muscle responses or adaptations (clin-
ical or physiological), (2) reviews that covered articles
that were already included in this scoping review and (3)
pharmacological intervention at the same time of the ex-
ercise or training protocol. After the initial screening,
the remaining articles were fully read and screened ac-
cording to the same criteria by the same independent re-
viewers (M-PR and MM). In case of a disagreement,
both reviewers discussed about the eligibility of the
study. If a consensus was not reached, a third reviewer
(ED) was consulted.
Charting the data
The data from the selected studies were then charted by
one reviewer (M-PR) and reviewed by a second reviewer,
a second-year physical therapy student with two years of
experience as a research trainee in our lab, according to
a data extraction grid to ensure standardized data ex-
traction (Table 1). By working exclusively on projects fo-
cusing on DM1, both evaluators have some knowledge
of the disease. Moreover, their training in physical ther-
apy along with their experience as trainee in wet lab
make them familiar with the continuum of outcome
measures found in the literature. A beta version of the
extraction grid was tested on three articles before the
final grid was produced.
Collating, summarizing and reporting the results
The results were summarized under two main themes:
outcome measures and exercise or training protocols. The
outcome measures were subdivided in clinical measure-
ments and physiological variables (top of Additional file 2).
Clinical measurements were categorized as intervention
outcomes (patient-reported outcome measures, functional
tests, muscle endurance tests, aerobic capacity tests,
muscle strength tests and other) and sub-categorized into
specific measure types. Physiological variables were
categorized as laboratory tool (myography, magnetic res-
onance imagery (MRI), muscle biopsy analysis and blood
tests) and sub-categorized into studied physiological
variables. Each of these sub-categories can be seen in
Additional file 2. There were two types of exercise or
training protocols: single session exercise and training
programs. The type of training programs used (far left col-
umn of Additional file 2) were categorized as: neuromus-
cular electric stimulation (NMES), strength training,
aerobic training, balance training and multiple rehabilita-
tion interventions. Also, as the detailed protocol of some
clinical measurements were not standardized, mostly
Table 1 Data extraction grid
Title/Journal
Author(s)
Year
Study eligibility
Country
Aims/Objectives
Diagnostic criteria, inclusion/exclusion criteria and phenotype
Number of DM1 participants and protocol compliance
Sex
Age
Other clinical manifestations of DM1 considered
Study design and exercise or training protocol (detailed)
Muscles targeted by the exercise or training protocol
Clinical measurements and detailed protocol
Physiological parameters evaluated
P value, confidence interval
Results (detailed)
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concerning muscle endurance, aerobic capacity and
strength testing, information needed to reproduce
them were assessed and classified by two independent
reviewers (M-PR and the second-year physical therapy
student). If there was a disagreement, a third reviewer
would decide (ED).
Results
The detailed steps of the systematic literature search can
be found in the PRISMA flow chart (Fig. 1) [27]. A total
of 704 papers were identified following the systematic
search, from which 43 were selected based on title and
abstract. These 43 papers were entirely read and both re-
viewers (M-PR and MM) excluded 22 papers according
to inclusion and exclusion criteria (Fig. 1 for reasons of
exclusion).
Study characteristics
Detailed information regarding the selected papers can
be found in Table 2. Within the twenty-one selected
studies, four were randomised controlled trials (RCT) [2,
28–30], twelve had before-after designs [3, 24, 31–40],
two were cross over studies [41, 42], one was retrospect-
ive [43], one was a case study [44] and one was a case
report [45]. Sample size varied between 1 and 35 partici-
pants depending on the design with most studies with
before-after design or RCT with a sample size ranging
from 10 to 35 DM1 participants.
Exercise and training protocols
(Left column of Additional file 2). Different exercise or
training protocols have been used to study muscle re-
sponses or adaptations. As expected, single session
exercises were done under supervision [31, 34, 36–40].
Regarding training programs, seven were done under
healthcare professional supervision [24, 29, 33, 43–45],
two presented a mixed supervision (professionally super-
vised and home-based sessions) [28, 41], one was done
under parent’s supervision [42] and four were performed
at home, then without supervision [2, 3, 30, 32].
Clinical measurements
(Upper row – left of Additional file 2). Many standard-
ized functional tests were used (Additional file 2), some
studies used technology to assess function (Missaoui et
al. 2010 [43]: a Statel stabilometer to assess balance and
a locometer as a computer assisted movement analysis
to evaluate gait) and homemade clinical functional tests
such as measuring the time needed to do transfers (Lin-
deman et al. 1995 [30] and Conraads et al. 2002 [45]).
Muscle endurance testing, strength testing, aerobic cap-
acity and other clinical measurements are further de-
tailed in Additional file 2. Many different clinical
measurements were given throughout the selected stud-
ies and most of them relied on highly standardized pro-
tocols, however, this is not always the case. Therefore,
the studies that included these types of measures were
listed and reproducibility of their protocol was evaluated
(Table 3).
Physiological variables
(Upper row – right of Additional file 2). Surface electro-
myography (SMEG) was the only method used to assess
muscle electric activation within the included studies [2,
32, 34, 36, 40]. Esposito et al. 2017 [34] introduced
mechano myography (MMG) to evaluate the degree of
Fig. 1 Flow chart results of the systematic literature search according to the PRISMA statement [27]
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muscle mechanical activation. Blood tests were used by
Siciliano et al. 2001 [38] to assess exercise-induced blood
lactate levels as an indicator of mitochondrial function.
Blood myoglobin levels were used in another study [30]
to ensure that training did not induce negative effects.
MRI was used to evaluate different muscular variables:
1) quadriceps muscle volume [24, 33, 44], 2) fatty infil-
tration of the tibialis anterior [33], 3) intramuscular pH
[31, 39, 44] and 4) bioenergetics, such as adenosine
tri-phosphate (ATP), inorganic phosphate or phospho-
creatine (PCr) [31, 39, 44]. Muscle biopsy was used to
assess muscle bioenergetics (ATP and PCr) in a study
conducted by Rehunen et al. 1985 [37]. It was also used
by Orngreen et al. 2005 [3] to determine capillary dens-
ity. Then, fiber type was assessed in two different studies
[24, 37] and muscle fiber cross sectional area (CSA) was
also evaluated in two papers [3, 24]. The proportion of
centrally nucleated fibers (CNF) was evaluated in one
study [24].
Outcome types
Main outcome types of included studies can be found in
Table 2. During the analysis of the effect of exercise or
training on skeletal muscle in DM1, it appeared that the
type of outcomes should be analyzed through two types
of intervention, as their natures are completely different:
muscular responses induced by acute exercise (single
session) and muscular adaptations induced by training
programs are thus presented separately.
Single session exercise
Regardless of the assessment method used, MRI or bi-
opsy, all three studies measuring bioenergetics showed
faster PCr and ATP depletion during exercise in DM1
patients in comparison to unaffected individuals [31, 37,
39]. One of these three papers showed an increased
intramuscular PCr concentration at rest compared to
unaffected individuals [37]. One of these papers along
with one using blood tests to evaluate blood lactate
levels suggested mitochondrial defects [31, 38], but
Barnes et al. 1997 [31] supported that this mechanism
was not the main reason why DM1 patients experienced
muscle weakness and wasting. All two studies [31, 39]
evaluating intramuscular pH, reported higher pH
post-exercise and a quicker return to normal levels of
pH post-exercise. Strength testing, in all three studies,
showed lower maximal strength [34, 36, 40] and longer re-
laxation time compared to healthy controls [34, 36, 40],
which are consistent with muscle weakness and myotonia
experienced by patients with DM1. In one of two studies
evaluating muscle endurance [40], a longer time before fa-
tigue (evaluated by calculating the time that the patient is
able to maintain a 50% maximal strength contraction) was
reported in DM1 individuals in comparison to unaffected
ones. In contrast, the other study evaluating muscle en-
durance, Esposito et al. 2017 [34] reported that rhythmic
6 s contractions at 50% of maximal strength led to the
same time to exhaustion between DM1 and unaffected in-
dividuals. In the two studies evaluating root mean square
(RMS) of electromyography (EMG) signal (an indicator of
Table 3 Clinical measurements standardization
Muscle endurance Aerobic capacity Strength
Time at
50 % max
strength
Time at
80 % max
strength
Submaximal
cycling and
walking
VO2 max (cycling),
heart rate and gas
exchanges
1 RM Isokinetic and
isometric computer
assisted device
MMT Force gauge
(handheld or
fixed)
Aldehag 2005 [41] O
Aldehag 2013 [28] O
Chisari 2013 [32] O
Conraads 2002 [45] X X X
Cudia 2016 [33] O
Esposito 2017 [34] O O
Hammarén 2015 [35] O
Lindeman 1995 [30] O O
Lindeman 1999 [2] O X
Missaoui 2010 [43] X
Nitz 1999 [36] X
Orngreen 2005 [3] X
Sjögreen 2010 [42] O O
Tollbäck 1999 [24] O O
Torres 1983 [40] O O
Legend: O: sufficient data for precise reproduction of protocol. X: insufficient data for precise reproduction of protocol
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physiological electrical activity), one found RMS increased
compared to unaffected individuals [36] and continued to
increase with repetitions of exercise while the other found
no significant differences of RMS between DM1 and con-
trol subjects during exercise [34].
Training programs
Positive effects of training programs on patient-reported
outcomes, such as improved self-perception of occupa-
tional performance, are found in all five studies measur-
ing this outcome [3, 28, 30, 35, 41]. Lindeman et al.
1999 [2] showed a significant increase in muscle endur-
ance while Lindeman et al. 1995 [30] showed a trend to-
wards increased muscle endurance. In addition, Sjögreen
et al. [42] showed an increase in muscle endurance in
some participants. These were the only three studies that
evaluated the effect of a training program on muscle en-
durance. Aerobic capacity was improved in both studies
that evaluated it [3, 45], with one study showing an im-
provement in respiratory function [45]. Improvement in
functional tests was found in four studies of the ten
studies that included them [32, 33, 41, 43]. All the other
studies showed no change except for a decreased per-
formance in the 10m walk test (10mwt) that was re-
ported by Hammarén et al. 2015 [35], in which they
hypothesized it was due to a greater caution from the
patients because they might be better aware of the risk
of falling. Maximal strength improvement was reported
in nine out of eleven studies that measured it [24, 28,
32, 33, 35, 41–43, 45]. It is to be noted that in some of
these studies, strength improvement was not observed
in all participants, in all muscle groups trained or in dif-
ferent assessment methods [24, 28, 32, 33, 35, 41, 42].
One study reported loss in maximal strength in some
patients [35]. One study out of two showed an
exercise-induced normalization of electromyographic
patterns through SMEG evaluation [32]. Bioenergetics
(ATP and PCr) were normalized without a change in ab-
normal pH in the only study that evaluated it following
a training program [44]. One study out of three reported
a slight increase in muscle volume through MRI [44].
The two studies that used muscle biopsies to assess
muscle fiber CSA reported an increase, one only a trend
in type I fibers [24] and one in both type I and type IIa
[3]. These findings are encouraging because they support
muscle growth. Fiber type and capillary density were not
reported to change [3, 24]. The only study evaluating
these factors reported an increase in CNF [24] and un-
changed blood myoglobin levels were also [30].
Discussion
The aim of this scoping review was to map out what is
known about the effects of exercise or training program
used to counteract muscle impairments in people affected
by DM1 in order to guide future research. There is an
obvious lack of studies available to fully comprehend mus-
cular immediate responses and long-term adaptations to
exercise or training and some domains have been insuffi-
ciently or have not yet been investigated (Fig. 2). More lit-
erature related to exercise or training could be particularly
useful for healthcare professionals, such as physical thera-
pists, who need to know the right type and dosage of exer-
cise to prescribe to their patients to limit the progression
of muscle impairments. Although the majority of studies
report no adverse effects of exercise or training, there is
no evidence supporting positive effects and data are insuf-
ficient to have a clear understanding of the optimal pa-
rameters to use with this population. A previous
systematic review has also showed no adverse effects of
strength training in people with DM1 [25].
Being a scoping review, the methodological quality
of the different studies has not been assessed and this
constitutes a limit to the interpretation of the out-
comes reported in the different studies. Furthermore,
as the exercise and training protocols and outcome
measures were highly heterogenous, data pooling is
not yet a feasible option. As shown in this scoping
review, there is no sufficient similar high-quality evi-
dences available to carry out a systematic review or a
meta-analysis with a research question such as “What
is known about the effects of exercise or training that
aim to reduce skeletal muscle impairments of patients
with myotonic dystrophy type 1?”. One preferred de-
sign seems to be before/after or crossover designs,
which may be better suited for studies where few par-
ticipants are available [46].
Exercise and training protocols have been separated
into two types to facilitate the analysis. Single session ex-
ercise studies allowed the understanding of the early
muscle responses to exercise of people with DM1 in
comparison to controls. On the other hand, training
programs gave information about muscular adaptations.
These can lead to a better understanding of the benefits
of long-term training and thus help healthcare profes-
sionals to choose an appropriate rehabilitation approach
to manage skeletal muscle impairments. Studies using
single session exercise have used more physiological var-
iables to assess efficacy while studies using training pro-
grams tended to use more clinical measurements. This
is not surprising since a short (unique) stimulus is not
expected to induce clinically significant changes. How-
ever, the inclusion of physiological variables in studies
using training programs would have given an important
insight of the cellular and molecular mechanisms sup-
porting the changes in clinical outcomes. This scoping
review has outlined that the focus in the physiological
variables was on muscle conductivity, bioenergetics,
mitochondrial activity, intramuscular pH, centrally
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nucleated fibers and muscle fiber type and size. While it
is known in DM1 that skeletal muscle has multiple alter-
ations in inflammatory status, myogenesis and protein
synthesis/degradation balance [1, 18–22], there are, to
this day, no studies that consider the impact of exercise
or training on these aspects. This knowledge would be a
key component to help to understand why patients do
not all show the same response to exercise or training
throughout the different studies, thus leading to a better
comprehension of the dosage and type of exercise or
training that should be prescribed to obtain optimal
results.
It is to be noted that at the time period when the sys-
tematic search was conducted, no animal studies about
the effect of exercise in DM1 were found. This scoping re-
view was thus directed on human studies only. It is only
very recently (January 2019) that the first animal model
study was published to assess the effect of exercise in
DM1 (access to a running wheel for 7 weeks) by Manta et
al. [47] This study demonstrates very interesting results
about the effect of exercise in DM1: it improves strength
and endurance, normalizes electromyographic signal (an
indication of reduced myotonia), increases mitochondrial
content, decreases accumulation of CUG RNA resulting
in a decreased sequestration of MBNL-1 among other
physiological benefits [47]. These results are consistent
with some uncovered in this scoping review where exer-
cise had beneficial effects on strength [24, 28, 32, 33, 35,
41–43, 45], endurance [2] or electromyographic signal
[32]. However, many of the physiological outcomes mea-
sured by Manta et al. have not yet been measured in
humans, showing another gap in current scientific
literature.
From a clinical standpoint, this scoping review showed
that there is a major lack in the body of evidence
available to help clinicians to base their rehabilitation in-
terventions on solid literature for their DM1 patients. In
addition, compliance of patients to participate to a re-
habilitation intervention therapy can be hampered by
other symptoms since DM1 is a multisystemic disease
[9]. For example, it has been shown that 40% of patients
with DM1 suffer from apathy [48]. This can have a
major impact on the reported outcome of exercise and
training. Cardiac impairments are also frequently re-
ported in DM1 [49], which can lead to restrictions in ex-
ercise and training participation. It is worth to be
mentioned that these are only a few examples of other
symptoms of DM1 that can interfere with exercise or
training, which should be investigated in the future.
A lack in the standardization of some clinical mea-
surements has also been observed between the selected
studies. This element is particularly important to control
with DM1 patients since many other confounding fac-
tors arising from the multisystemic nature of the disease
may already influence the results. An example of this is
strength testing, which represents one of the major out-
comes used to assess muscle adaptations following a
training program. The issue about lower limb strength
assessment in DM1 patients has already been evaluated
in further detail by a systematic review [50] where differ-
ent methods were described and very few of them had
sufficient methodological descriptions to allow protocol
reproducibility. In addition, manual muscle testing has
been shown to significantly lack sensibility and validity
to adequately measure muscle strength in DM1 popula-
tion [8]. In this scoping review, only two studies out of
15 that evaluate maximal strength used only MMT to
assess strength; however, this still represents 9% of the
accepted studies. Furthermore, these two studies were
the only ones using a NMES training program, which
Fig. 2 Mapping of current literature according to their type of measures. Each category (in bold) includes domains that can be influenced by
exercise or training. Number of publications (n) addressing each of these domains is indicated in parentheses (in bold and italic if this number is
≤5). CSA, Cross sectional area; CNF, centrally nucleated fibers
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greatly hampers the strength of the evidence regarding
this type of training.
Another interesting point brought on by Petitclerc et
al. 2017 is that adult and late-onset phenotypes should
not be pooled together to assess muscle strength be-
cause of their different maximal strength loss profile
over time [8]. Congenital, infantile, childhood onset phe-
notypes are already known to be even more clinically
different from the adult and late-onset phenotypes [49].
This brings the hypothesis that some methodological
risks are associated to the pooling of different pheno-
types when evaluating the effectiveness of an interven-
tion aimed at decreasing muscular impairments. In this
scoping review, many studies mixed different phenotypes
or do not even specify the phenotypes of their partici-
pants. Future studies should consider this important
element when recruiting their participants. Moreover,
many studies published after 1992 did not specify nor
did genetic testing to validate if their participants were
true DM1 patients. As the mechanisms underlying max-
imal muscle strength loss vary greatly between neuro-
muscular diseases, genetic testing should be a standard
procedure in DM1 research.
Conclusion
This paper maps and summarizes all existent literature
about the effect of exercise or training in humans with
DM1. We also offer a clear framework to guide future
studies. There is a great deal of research that still needs
to be done in order to fully understand how skeletal
muscles in DM1 patients respond to exercise and train-
ing. Many studies looked at neuromuscular function,
however there are still an insufficient number of RCTs
to come to clear conclusions. Furthermore, no studies
have yet evaluated the effects of exercise or training on
muscle proteomics, that are essential to understand the
underlying mechanisms of the observed adaptations.
Once a better understanding will be reached, clinicians
will be able to prescribe interventions more effectively
and thus better manage muscle wasting and weakness.
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